Skip to main content Accessibility help
×
Home
Hostname: page-component-65dc7cd545-pxrsg Total loading time: 0.19 Render date: 2021-07-24T22:08:38.976Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Safety, Not Only Efficacy Still to be Proven for Controversial New MS Treatment

Published online by Cambridge University Press:  18 February 2016

Marcelo Kremenchutzky
Affiliation:
London Health Sciences Centre London, Ontario, Canada
Rights & Permissions[Opens in a new window]

Abstract

Image of the first page of this article. For PDF version, please use the ‘Save PDF’ preceeding this image.
Type
Editorial
Copyright
Copyright © Canadian Neurological Sciences Federation 2011

References

1.Smith, CM. Origin and uses of primum non nocere - above all, do no harm! J Clin Pharmacol. 2005;45(4):371–7.CrossRefGoogle ScholarPubMed
2.Kremenchutzky, M, Walt, L. Lack of congruence in the ratings of patients' health status by patients with MS and their physicians. Neurology. 2010;74(9) Suppl 2:A364.Google Scholar
3.Burton, JM, Alikhani, K, Goyal, M, et al. Complications in MS patients after CCSVI procedures abroad (Calgary, AB). Can J Neurol Sci. 2011;38(5):741–6.CrossRefGoogle Scholar
4.Zamboni, P, Galeotti, R, Menegatti, E, et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg. 2009;50:1348–58.CrossRefGoogle ScholarPubMed
5.Samson, K. Experimental multiple sclerosis vascular shunting procedure halted at Stanford. Ann Neurol. 2010;67:A1315.CrossRefGoogle Scholar
6.Ludyga, T, Kazibudzki, M, Simka, M, et al. Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe? Phlebology. 2010;25(6):286–95.CrossRefGoogle ScholarPubMed
7.Petrov, I, Grozdinski, L, Kaninski, G, et al. Safety profile of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Endovasc Ther. 2011;18:314–23.CrossRefGoogle ScholarPubMed
8.www.fda.gov [homepage on the Internet]. What is a serious adverse event? [updated 2011 Jun 23; refd 2011 Jun 30]. Available from: http://www.fda.gov/safety/medwatch/howtoreport/ucm 053087.htm.Google Scholar
You have Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Safety, Not Only Efficacy Still to be Proven for Controversial New MS Treatment
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Safety, Not Only Efficacy Still to be Proven for Controversial New MS Treatment
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Safety, Not Only Efficacy Still to be Proven for Controversial New MS Treatment
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *